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The main aims of this review were to understand the roles of gene therapy in the treatment and prevention of type 1 diabetes mellitus and 
I will discuss a brief history, approaches, vector types with the future of diabetes following clinical use. Type 1 diabetes mellitus is a 
metabolic condition that is identified by insufficient insulin development due to pancreatic damage to beta cells. Control, long life, and 
diagnosis of these metabolic disorders have become vital sources for many scientists and researchers. After 2000, the latest approaches to 
molecular medicine were introduced as one of the possible therapeutic options for diabetes type 1 diagnosis. Many genes have been 
reported as a clinical trial so that damaged genes can be treated and three main approaches shown about 50 years ago are islet 
transplantation, β cell regeneration, and insulin gene therapy to cure and prevent diabetes type. Treating diabetes through gene therapy can 
promise children and adolescents, but more clinical applications are needed to recognize it as a permanent route. 
 





Diabetes is one of the metabolic disorders characterized 
by hyperglycemia due to insulin secretion deficits, 
insulin action, or both (Smail et al., 2019). Type 1 
diabetes mellitus is caused by extreme insulin deficiency 
secondary to pancreatic beta cell autoimmune damage 
(Kolodka et al., 1995). The Middle East and North 
Africa region have the highest average prevalence of 
diabetes in adults (10.9%), while the Western Pacific 
region has the largest number of adults diagnosed with 
diabetes and the highest prevalence of diabetes in 
countries (37.5%). In terms of diagnostic criteria, 
etiology, and genetics, various classes of diabetes 
mellitus, namely type 1, type 2, gestational diabetes, and 
other types of diabetes mellitus are compared 
(Kharroubi et al., 2015). 
Gene therapy is a new form of molecular medicine 
that will have a significant impact on human health in 
the next century (Verma et al., 2000). Visionary 
scientists had hypothesized almost five decades ago that 
genetic modification by exogenous DNA could be an 
effective treatment for inherited human diseases. This 
strategy of “gene therapy” offered the theoretical 
advantage that one single treatment would achieve a 
lasting and possibly curative clinical benefit (Dunbar et 
al., 2018). Recent gene therapy clinical trials have 
shown considerable therapeutic benefits and an excellent 
safety record. They show the long-sought-after potential 
of gene therapy to provide 'cures' after certain 
potentially terminal or seriously disabled disorders 
(Naldini, 2015). To date, approximately 2600 clinical 
trials on gene therapy have been completed, are 
underway, or licensed worldwide (Ginn et al., 2018). 
Gene therapy is intended to inject genetic material 
into patient cells to compensate for damaged genes or to 
include therapeutic transgenes. Gene therapy has 
advanced from the initial human gene transfer trials to 
approved clinical therapies over the past three decades 
(Wang et al., 2020). Modern therapeutic strategies seek 
to restore the endogenous insulin production rather than 
traditional insulin injection treatment (Memon and 
Abdelalim 2020). Differentiation of insulin-producing 
pancreatic β cells from induced pluripotent stem cells 
(iPSCs) originating from diabetes patients aims to 
provide autologous cells for cell replacement therapy for 
diabetes. Present methods, however, generate patient 
iPSC-derived β (SC-β) cells with low in vitro and in 
vivo function (Maxwell et al., 2020). In several ways, 
cell replacement therapy for type 1 diabetes (T1D) is a 
perfect first drug model to follow in the emerging field 
of regenerative medicine (Brandon et al., 2020). 
 
History of Gene Therapy 
The ideas of gene therapy emerged in the 1960s and 
early 1970s, while in 1968 Rogers & Pfuderer 
demonstrated a proof of concept for virus-mediated gene 
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marked cell lines and explanation of the polyoma and 
SV40 papovavirus mechanisms of cell transformation 
(Friedmann, 1992). Modern transfection methods were 
combined with cultured cell selection systems and 
recombinant DNA technology in the late 1970s.The 
possibility of successful gene transfer into mammalian 
cells for gene therapy purposes was generally 
recognized with the creation of retroviral vectors in the 
early 1980s (Wolff et al., 1994). However, clinical 
efficacy in a small-scale clinical trial curing an 
otherwise fatal immunodeficiency disorder in children 
could not be demonstrated until the start of the new 
century (Escors et al., 2010). Pancreatic transplantation, 
first performed in 1966, exists in the new millennium as 
a radical treatment for particularly intractable type I 
diabetes with advanced complications. Gene therapy 
with molecules like leptin and insulin, still in 
experimental mode, may one day become a reality 
(Lakhtakia, 2013). Clinically active islet-free implants 
began in 1989 which require immunosuppression for 
long life. For more than 30 years, several encapsulated 
islet approaches have been ongoing without the 
definition of a clinically relevant product (Scharp et al., 
2014). 
 
Approaches for Gene Therapy in Type 1 of Diabetes 
A cure for type 1 (insulin-dependent) diabetes could be 
found to replace β cells in the generation of surrogate 
insulin-producing cells (Samson and Chan, 2006). 
Several different approaches have long been used to 
seek a cure for diabetes, including islet transplantation, β 




The idea of T1D cell replacement therapy remained 
dormant for 80 years until 1972 when Ballinger and 
Lacy reversed chemical diabetes by islet transplantation 
in rats (Shapiro, 2012). Following the success of steroid-
free immunosuppression transplantation of fresh human 
islets (Froud et al., 2005). The inexorable decline in 
insulin independence following islet transplantation 
alone (ITA) has raised concerns regarding its clinical 
utility (Bellin et al., 2012). Allotransplantation of islets 
into patients with autoimmune type 1 diabetes is a re-
exposure to autoantigen (Bosi et al., 2001). Although 
immunosuppression protocols have improved islet 
transplant outcomes, more research is required to 
maximize islet availability for transplantation and 
improve the viability of islets once transplanted 
(Zarinsefat and Stock, 2020). Islet transplantation in 
patients with type 1 diabetes can reduce or eliminate the 
insulin requirement. Exenatide is a long-acting 
glucagon-like peptide-1 (GLP-1) analog that increases 
glucose-induced insulin secretion and may increase the 
mass of β cells (Al et al., 2007).  
Glucagon responses of islet transplant recipients to 
hypoglycemia were significantly lower than those 
observed in control subjects (incremental glucagon 
[mean ± SE]: −12 ± 12 vs. 64 ± 22 pg/ml, respectively; 
P < 0,05), and not significantly different from those of 
non-transplant type 1 diabetic subjects (−17 ± 10 pg/ml) 
(Paty et al., 2002). A glucose-potentiated arginine test, 
conducted only in insulin-independent transplant 
subjects (n = 5), showed significant impairments in the 
glucose-potential slope (P < 0.05) and the maximum 
response to arginine (ARmax; P < 0.05), a measure of β-
cell secretory capacity. Because ARmax provides an 
estimate of the functional β-cell mass, these results 
suggest that the functional defects observed after islet 
transplantation may account for a low engrafted β-cell 
mass (Rickels et al., 2005). 
Moreover, approximately 70 percent of transplanted 
Type 1 diabetic patients achieved insulin independence 
(Matsumoto, 2010). By contrast, a clinical review at the 
BMJ in 2001 anticipated that transplantation of 
Langerhans islets would be the treatment of choice for 
most Type 1 patients diabetes by 2010. Islet 
transplantation is currently an option for a specific group 
of patients with type 1 diabetes only — those with 
severe glycaemic lability, recurrent hypoglycemia, and 
unawareness of hypoglycemia (de et al., 2011). IAK was 
associated with better glucose control and a slower 
decrease in eGFR than standard insulin therapy in 
patients with type 1 diabetes and a functioning kidney 
transplant (Maanaoui et al., 2020). In this first double-
blind randomized trial, the islet transplant evidence 
obtained with reparixin does not support the role of 
CXCR1/2 inhibition in preventing inflammation-
mediated damage to the islet (Maffi et al., 2020). 
 
Regeneration of β Cells 
One goal of regenerative medicine is the instructive 
incorporation of adult cells into other forms of cells for 
tissue repair and regeneration (Zhou et al., 2008). Two 
major efforts are underway to address the β-cell diabetes 
deficit: one would produce ex vivo β-cells that are 
appropriate for transplantation, and the other would 
promote β-cell regeneration in the pancreas (Bonner et 
al., 2005). The regeneration of pancreatic β cells which 
produce insulin is a key therapeutic strategy for diabetes 
(Ackeifi et al., 2020). Through adulthood, β cell mass 
increasing the ability to suit peripheral requirements. 
Insufficient insulin secretion by β cells leads to Mellitus 
diabetes (Teta et al., 2017). Pancreatic insulin-producing 
β-cells have a long lifespan, so they replicate very little 
during a lifetime in healthy conditions (Thorel et al., 
2010). Regeneration of pancreatic β-cell mass following 
either toxin- or autoimmune-mediated destruction in 
young rodents is probable, but the degree of recovery 
declines with age and is incomplete in adult life. 
Similarly, in children and adolescents with type 1 
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neogenesis and regenerative response (Thyssen et al., 
2006). Single-cell RNA sequencing (scRNA-seq) of 
islets identified β-cell dedifferentiation and dysfunction 
markers and pathways (Sachs et al., 2020). 
Three regeneration modes were established 
according to the various cellular regeneration origins. In 
the first mode, the undifferentiated progenitor cells 
proliferate and differentiate as a self-renewing source in 
response to injury to repair the lost cell population. The 
second mode, de-differentiate, and then proliferate the 
highly defined remaining cells (Wang et al., 2020). 
Regeneration of lost or dysfunctional islet β cells in vivo 
can fulfill the promise of improved treatment for 
patients with diabetes. Numerous mitogenic factors have 
been attempted to achieve this, including gamma-
aminobutyric acid (GABA) (Yi et al., 2020). Results 
indicate that curcumin has anti-diabetic properties 
because of its superior immunomodulatory behavior on 
T-associated cytokines and immunosuppressive activity 
on pro-inflammatory cytokines may enhance damage to 
pancreatic β cells (Badr et al., 2020). Proliferation is the 
primary mechanism of b-cell expansion during the early 
postnatal period to produce sufficient b-cell mass in an 
organism. However, the proliferation of b cells declines 
rapidly in early life, and the rate of division of b cells in 
adults is very low (Guney et al., 2020). However, there 
is still a great need for new treatments, as TID remains 
an incurable illness. Natural products, primarily 
phytochemicals, are a tremendous source of drug lead 
discovery for diabetes (Apaya et al., 2020). 
Nevertheless, conventional cell-based research 
approaches have weaknesses in identifying the precise 
processes of β-cell differentiation and trans-
differentiation, as well as the related regulatory 
mechanisms (Yu and Xu, 2020). 
Data cumulated over the past few years suggest that 
increased β-cell dedifferentiation plays a crucial role in 
diabetes progression, shedding new light on potential 
targets for β-cell replacement therapy (Zhang et al., 
2020). Based on a new understanding of structural and 
functional dynamics of the bone marrow, a 
conditioning-free bone marrow transplantation (BMT) 
with reduced adverse effects opens the possibility of 
evaluating β cell regeneration and euglycemic 
restoration by inducing allogeneic chimerism in T1DM 
patients, as shown in a mouse model (Black and Zorina, 
2020). A new study now shows that a pharmacological 
combination of insulin and GLP-1–estrogen conjugate 
not only decreases the daily requirements for insulin but 
also improves β-cell function (De et al., 2020). LIF 
receptor expression is limited to a subset of 
transcriptionally isolated human β cells with the 
enhanced proliferative ability (Rosado et al., 2020). 
Residual β-cells play a major role in the design of 
clinical trials: they may not only respond to combination 
therapies that involve metabolic function stimulants but 
are also the possible source of new β-cells (Akirav et al., 
2018). 
Insulin Gene Therapy 
Insulin treatment options for type 1 and type 2 diabetics 
have increased since the launch of the insulin analogs in 
1996. Insulin therapies are now able to mimic the 
physiological insulin secretion more closely and thus 
achieve better glycemic control in diabetes patients 
(Donner et al., 2019). Gene therapy is one of the 
diabetes mellitus treatment methods (Ramezani et al., 
2019). The two key issues are efficacy and safety in 
developing insulin-replacement gene therapy as a 
possible treatment for type 1 diabetes. In addition to 
using a safe and efficient gene transfer vector, the 
physiological regulation of the expression of the insulin 
gene is important (Chen et al., 2011). Insulin gene 
therapy refers to the targeted expression of insulin in 
non-β cells, the primary therapeutic target being 
hepatocytes (Handorf et al., 2015). The human insulin 
gene wrapped in chitosan nanoparticles can be 
successfully transfected through the gastrointestinal tract 
into rats (Niu et al., 2008). 
Differentiation between ADSC and tissue-specific 
promoters will improve the therapeutic gene expression. 
The use of microcarriers can facilitate post-
transplantation cell survival and hold potential for long-
term cell therapy (Fang et al., 2019). Insulin-producing 
cell replacement through transplantation shows 
significant promise but is limited in application due to 
supply constraints (cadaver-based) and chronic 
immunosuppression. Important progress has been made 
over the past decade in tackling these obstacles to broad 
cell therapy adoption (Latres et al., 2019). The 
possibility that the risk variants of BACH2 and 
CLEC16A could contribute to the development of 
insulin-triggered type 1 diabetes cannot be excluded in 
addition to the type 1 diabetes high-risk human 
leukocyte antigen class II and the class I allele of the 
insulin gene variable number tandem repeat genotype 
(Onuma et al., 2019). 
Therapeutic studies assess the efficacy of antigen-
specific and antigen-nonspecific immune therapies, 
which also include reconstruction of the damaged beta-
cell mass via islet transplantation, neogenesis, and 
regeneration, and their combinations (Van et al., 2011). 
Cells that express insulin and have molecular 
characteristics that closely resemble bona fide insulin-
secreting cells have been produced by the most effective 
protocols to date; however, these cells are often non-
responsive to glucose, a feature that should be addressed 
in future protocols (Aguayo et al., 2010). Such 
beneficial effects of leptin are not underpinned by 
pancreatic β-cell regeneration, since circulating insulin 
levels were undetectable at basal and glucose overload 
levels (Fujikawa et al., 2010). However, contrary to 
insulin monotherapy, leptin reduces both lipogenic and 
cholesterologenic transcription factors and enzymes, and 
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Prevent of Type 1 of Diabetes by Gene Therapy 
Since no existing targeted immunotherapies are 
currently unable to replace the normal insulin delivery, it 
is important to have a deep understanding of T1D 
pathophysiology to prevent T1D development (Kaur, 
2020). The study shows that AAT gene therapy 
decreases cell-mediated autoimmunity, changes the 
repertoire of T-cell receptors and effectively prevents 
type 1 diabetes in the NOD mouse model. These 
findings strongly suggest that AAT gene therapy 
mediated by rAAV1 may be useful as a novel approach 
to preventing type 1 diabetes (Lu et al., 2006). The data 
indicate that expression of defensive MHC class II 
alleles in bone marrow-derived cells provides robust 
self-tolerance to islet autoantigens and is adequate to 
prevent recurrence of autoimmune diabetes following 
islet transplantation (Tian et al., 2007). 
Dual activity of heparanase inhibitors / HS replacers 
as a novel therapeutic class to prevent T1D progression 
and potentially to mitigate secondary vascular disease 
developed with long-term T1D (Simeonovic et al., 
2020). An independent study showed that the optimal 
rise of GCs in beta-cells was a compensatory 
mechanism that prevented high-fat diet-induced beta-
cell failure (Cobo et al., 2020). The role of combination 
therapy in the prevention of diabetic cardiomyopathy, 
without forgetting the major contribution of insulin, the 
preferred medication for the treatment of T1DM 
(Cieluch et al., 2020). In several chronic diseases, 
including T1D, a large number of proinflammatory 
ligands that can signal via RAGE have been implicated. 
It is therefore unbelievable that RAGE has become a 
possible therapeutic target for disease treatment and 
prevention (Le et al., 2020). As an antigen-specific 
monotherapy, ADi-100 is highly e cacious in reversing 
elevated hyperglycemia to prevent diabetes, where a 
promising feature of immune tolerance is the increased 
apoptosis-inducing BAX content (Alleva et al. ,2020). It 
has been shown that the formulated autoantigenic islet 
peptides (GAD65206-220, GAD65536-550, Insulin B9-
23, and C17-A1) used as a tolerogenic vaccine 
prevented T1D from developing in prediabetic NOD 
mice (Zhou et al., 2020). 
The coxsackievirus B association with the onset of 
T1DM has been observed. Accurate trigger detection 
will contribute to the creation of suitable preventive 
steps. It can become a foundation for advanced clinical 
studies to prevent T1DM (Desai et al., 2020). 
Recognizing that T1D is primarily an autoimmune beta-
cell disorder that only in its final stage progresses to a 
metabolic syndrome will expand therapeutic options for 
earlier intervention and improve the prospects for 
prevention (Desai n et al., 2020). Gene expression with 
immuno-regulatory capacity may potentially decrease 
allograft rejection. Recent studies have shown that viral 
interleukin (IL)-10 can decrease immune response 
during allotransplantation and is one of the most 
promising methods for preventing rejection (Jeong et al., 
2020). 
 
Vectors for Gene Therapy in Diabetic 
Virus vectors were used as gene transfer vehicles for 
various applications in preclinical and clinical gene 
therapy and with the approval of Glybera (Alipogene 
tiparvovec) as the first gene therapy product as standard 
medical treatment (Goins et al., 2020). The use of 
viruses as carriers of genetic products requires a detailed 
and thorough understanding of viral vectors from viral 
preparation to clinical use (Afzal et al., 2020). 
Adenoviral vectors as one of the most common groups 
used in gene therapy have a high human capacity. They 
're not actually integrated into the host genome 
(Arjmand et al., 2020). In a cerebellar granule cell 
culture (CGC), treatment with GAD cDNA-containing 
HSV vectors increases GAD65 and GAD67 expression 
and GABA release evoked by stimulation (Kanao et al., 
2020). The definition of AD, AAV and LV (Shirley et 
al., 2020) is given on the other hand to competent (RC) 
viral vectors (De et al., 2020). The advantage of 
adenoviral vectors over retroviral vectors is that they can 
transduce both dividing and non-dividing cells and can 
be prepared in high titers. Adenoviruses can infect 
insulin-secreting cells, and it has been shown that they 
can transduce rodent islets (Borkar et al., 2020). 
Co-precipitation of calcium phosphate is a simple 
and cheap method for the genetically modified 
pancreatic cells being non-viral vectors (Wong et al., 
2010). Nearly all of the non-viral vectors used to date 
are plasmids of expression that were engineered for high 
expression when transmitted to striated muscle or other 
cells (Prud et al., 2007). Non-viral HVJ liposome-
mediated human HGF gene transfer has potential for 
safe and successful diabetic sensorimotor neuropathy 
treatment (Kato et al., 2005). 
 
Future gene Therapy in Diabetes: 
In the future, therapeutic strategies should be 
personalized, given the high variance in genetics and 
islet autoimmunity among patients (Liu et al., 2020). 
The recent increase in global stem cell research funding 
is largely based on the promise to translate scientific 
understanding of stem cells into regenerative medicine 
(Wainwright et al., 2006). As the approaches to 
immunotherapy have remained unsuccessful, 
transplantation of donor-derived pancreas or islets is the 
only cure for T1D (Aghazadeh et al., 2017). The urgent 
need for a much anticipated insulin-secreting substitute 
for β-cells led researchers to focus on stem cells (SCs) to 
produce insulin-secreting β-cells. SC-based methods 
have opened up the new horizons to treat T1DM for 
being more precise and focused therapeutic approaches 
(Farooq et al., 2019). Replacing pancreatic islets with 
corpse-derived islets has proven to be a successful 
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them to be independent of exogenous insulin (Sluch et 
al., 2019). There was an explosion of interest in 
developing methods for transplantation to replace the 
islets lost during natural diabetes development (Emerich, 
2002). Clinically appropriate and healthy, the procedure 
is associated with a low risk of adverse effects (Ahrén, 
2011). Clinical trials to improve the engraving, the 
availability of insulin-producing cell sources and 
alternative transplant sites are currently under 
investigation to expand treatment (Bruni et al., 2014). 
Glucagon-like peptide 1(GLP-1) analogs and alternative 
insulin pathways, particularly oral (enteric-
gastrointestinal, inhaled) pathways, are now most 





I have come to the following conclusions from the 
review: The gene therapy production and uses have 
increased significantly over periodic time. Gene therapy 
has a reduced role in the secondary complication of 
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